The pharmaceutical implementation benchmark: what 4,957 assessments reveal
The pharmaceutical implementation benchmark is IMA Worldwide's pharmaceutical cut of its Implementation History Assessment archive: 4,957 assessment records from 20 pharmaceutical organizations, 2000 to 2024. Unlike single-year survey benchmarks, it holds one fifty-question instrument constant for twenty-five years. Its central finding: pharma scores like every other industry, and the widest internal gap sits between knowing who decides and having a say in it.
What does the pharmaceutical implementation record actually show?
IMA Worldwide evaluated its Implementation History Assessment (IHA) data from 2000 on. The assessment asks people who lived through previous changes fifty questions about how those changes actually landed, and scores the result across eleven conditions. The pharmaceutical cut of that archive covers 4,957 assessment records from 20 pharmaceutical organizations, 2000 to 2024.
The first finding is the one most likely to surprise a pharmaceutical executive, and it is not the one they brace for. Its mean readiness score of 61.0 is the same as the all-industry average of 61.0, and its profile tracks other industries to within a single point on every one of the eleven conditions.
The regulatory environment, the matrixed structure, the scientific culture: none of it produces a materially different readiness profile. What it produces is a harder setting in which to act on the same profile. The interesting pattern is not how pharma compares to everyone else. It is what sits inside pharma's own numbers.
Figure 1. Section scores for the pharmaceutical cohort, sorted lowest to highest. Every section sits in a narrow band between 54 and 67, which is why the overall average hides the story. Involvement is the floor and Structure is the ceiling, and Involvement is the only section where pharmaceutical organizations sit measurably below other industries.
Figure 2. 4 in 100 pharmaceutical assessment records describe an organization scoring High on readiness to implement, while 45.3 percent score Low or Very Low. n = 4,957 records from 20 pharmaceutical organizations, 2000 to 2024. Source: IMA Worldwide.
Why twenty-five years of it matters. Most change benchmarks are a single year of whoever answered. This is the same fifty-question instrument, put to people inside pharmaceutical organizations from 2000 to 2024, and the shape of the answer does not move.
Why do pharmaceutical transformations stall after go-live?
Look at the individual questions rather than the conditions and the pattern sharpens into something specific. Of all fifty items, the two pharmaceutical organizations score highest are about governance, and the two they score lowest are about participation. The distance between them is the finding.
| Assessment item | Pharma score | What it measures |
|---|---|---|
| Responsibility is defined | 3.63 | People know who owns what |
| Authority is defined | 3.47 | Decision rights are clear |
| Agents understand the reasons for the change | 3.39 | The people guiding it know why |
| Risk taking is rewarded | 2.69 | Room to try something new |
| Involved in the design | 2.61 | A say in what gets built |
| Turf guarding is rare | 2.51 | Work crosses functions freely |
| Change load is manageable | 2.49 | Capacity to absorb another change |
| Involved in the decision | 2.47 | A say in whether it happens |
Involved in the decision, at 2.47, is the lowest-scoring item of all fifty in the pharmaceutical cohort. Set it against defined responsibility at 3.63 and defined authority at 3.47, and the gap between knowing who decides and having a say in it is the widest in the instrument.
A pharmaceutical organization defines the change carefully, assigns it cleanly, resources it properly, and then discovers that the people expected to work differently were never part of building the thing they are now being asked to adopt. The plan is sound. The governance is real. The adoption is thin.
According to the AIM framework, that is the textbook definition of installation rather than implementation: the system goes live, the SOP is approved, the org chart is redrawn, and the behavior does not follow. Installation is the change being put in place. Implementation is people actually working the new way. Pharmaceutical organizations are unusually good at the first and structurally exposed on the second.
Figure 3. The pharmaceutical sequence. Every governed step scores at or near the top of the instrument. The one step that is not governed, bringing people into the decision and the design, scores at the bottom, and it sits directly between a system that is live and people who actually work the new way.
Change load compounds it. Manageable number of changes, at 2.42, is the second-lowest item in the cohort. When teams are already absorbing more concurrent change than they have capacity for, skipping the involvement step feels like the efficient choice. It is the most expensive one.
This is not a pharmaceutical failing. Defined responsibility and defined authority scoring at the top of a fifty-item instrument is a genuine organizational strength, and it is the direct product of operating in a regulated environment where accountability must be documented. The involvement gap is the predictable shadow of that strength, which is precisely why it responds to a deliberate method.
Questions the benchmark answers
Why do pharmaceutical transformations stall after go-live?
Pharmaceutical transformations most often stall because the people expected to work differently were never part of designing the change. Across 4,957 implementation assessment records from 20 pharmaceutical organizations, 2000 to 2024, the lowest scoring item of all fifty is being involved in the decision, at 2.47 on a 5 point scale, while defined responsibility at 3.63 and defined authority at 3.47 are the two highest. That gap between knowing who decides and having a say in it produces a well governed plan with no behavioral traction, which is the difference between installation and implementation.
How many pharmaceutical organizations score as ready to implement change?
About 4 in 100. In the pharmaceutical cohort of the IMA Worldwide assessment archive, 4.0 percent of records describe an organization scoring High on implementation readiness, while 45.3 percent score Low or Very Low, across 4,957 records from 20 pharmaceutical organizations, 2000 to 2024. That is the same distribution every other industry produces, which makes it a predictable structural condition.
Is the benchmark representative of the whole pharmaceutical industry?
No, and it does not claim to be. The cohort is client-weighted: 20 pharmaceutical organizations that engaged IMA Worldwide and ran the Implementation History Assessment, not a random sample of the industry. What it offers instead is consistency, the same fifty-question instrument applied inside pharmaceutical organizations for twenty-five years, which is what makes the internal pattern, governance high and involvement low, worth acting on.
What does the involvement gap mean for AI adoption in pharmaceutical organizations?
It predicts exactly where an AI rollout will stall. Involvement is the weakest item in the pharmaceutical cohort at 2.47, and AI asks scientists and quality professionals to change methods they have spent careers mastering. Research from Harvard Business School finds the primary psychological threat of AI at work is the erosion of competence and autonomy rather than job loss, so a change designed without the people who hold that expertise meets the strongest possible version of the involvement gap. The governance will be sound and the adoption will not follow.
How can we measure readiness before an AI rollout rather than after?
Readiness is a leading indicator, so it can be measured before usage data exists. The AI Readiness Pulse Check scores six dimensions of individual adoption readiness in about three minutes, including the Control dimension that corresponds to the involvement gap in this benchmark. Running it across a team shows the spread and the distance between the leadership view and the front line view, which is the practical starting point for closing the gap this data describes.
What to do with this profile: the method built to close the involvement gap, with the pharmaceutical engagement record behind it, is on the pharmaceutical change management page.
See your own version of this benchmark
The profile on this page is the pharmaceutical average. The useful version is yours: scored by site, function, or therapeutic area, against 20 pharmaceutical organizations across twenty-five years. Talk to IMA Worldwide about running the Implementation History Assessment on your portfolio.
Talk to IMA Worldwide about your portfolio See the assessments first